We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WES:NYSEWestern Midstream Partners, LP Analysis

Data as of 2026-05-28 - not real-time

$44.51

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Western Midstream Partners (WES) is trading at $44.51, comfortably above its 20‑day ($44.44) and 50‑day ($42.51) SMAs and well above the 200‑day SMA ($40.27), signaling a bullish price trend. The RSI sits at 52.6, indicating neutral momentum, while the MACD histogram is slightly negative, suggesting a short‑term bearish tilt within the broader uptrend. Volatility is elevated at 28.5% over the past 30 days, but the stock’s beta of 0.12 points to very low systematic risk compared with the market. Valuation metrics are attractive: the forward PE of 11.9 is well below the industry average of 20.7, and the DCF‑derived fair value of $53.31 implies upside potential despite a modest -2.8% downside adjustment. The dividend yield is a standout 8.36%, yet the payout ratio exceeds 100% (119.7%), raising questions about sustainability despite strong operating cash flow ($2.16B) and free cash flow ($0.89B). Recent Q1 2026 results delivered record adjusted EBITDA of $683M (+15% YoY) and distributable cash flow of $508.9M, supporting the current distribution of $0.93 per unit. Additionally, the announced acquisition of Brazos Delaware II could expand the asset base and enhance cash generation, providing a catalyst for future performance.
Overall, WES presents a blend of value and modest growth attributes, with a solid balance sheet and high yield but with dividend risk and commodity exposure that temper the upside. The low beta and strong cash metrics suggest a defensive profile, while the upcoming integration of the Brazos acquisition and continued earnings momentum support a buy‑on‑dip stance for medium‑term investors. However, the elevated payout ratio and sector‑specific regulatory and commodity price sensitivities advise caution, making a hold recommendation prudent for short‑term horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term moving averages indicating bullish bias
  • High dividend yield offset by >100% payout ratio
  • MACD bearish divergence suggesting limited upside in the near term

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued relative to peers (PE 14.6 vs industry 20.7)
  • Record Q1 earnings and strong free cash flow
  • Strategic acquisition (Brazos Delaware II) expanding cash‑generating assets

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable midstream cash flows supporting dividend continuity
  • Low systematic risk (beta 0.12) offering defensive characteristics
  • Exposure to energy‑sector regulatory and commodity price cycles

Key Metrics & Analysis

Financial Health

Revenue Growth22.50%
Profit Margin29.51%
P/E Ratio14.6
ROE36.69%
ROA7.35%
Debt/Equity248.29
P/B Ratio4.5
Op. Cash Flow$2.2B
Free Cash Flow$887.2M
Industry P/E20.7

Technical Analysis

TrendBullish
RSI52.6
Support$40.86
Resistance$48.01
MA 20$44.44
MA 50$42.51
MA 200$40.27
MACDBearish
VolumeStable
Fear & Greed Index92.34

Valuation

Fair Value$53.31
Target Price$43.27
Upside/Downside-2.78%
GradeUndervalued
TypeBlend
Dividend Yield8.36%

Risk Assessment

Beta0.12
Volatility28.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.